首頁 > 市場調查報告書 > 製藥

生物製劑分子標靶治療學

市場調查報告書

商品編碼

1831828

2025-2033年抗體藥物偶聯物市場報告（按成分、目標、應用、最終用戶和地區）

Antibody Drug Conjugates Market Report by Component, Target, Application, End User, and Region 2025-2033

出版日期: 2025年10月01日 | 出版商:

IMARC | 英文 146 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄圖表

2024 年全球抗體藥物偶聯物市場規模達 94 億美元。展望未來， IMARC Group預計到 2033 年市場規模將達到 502 億美元，2025-2033 年期間的成長率 (CAGR) 為 19.45%。

抗體藥物偶聯物 (ADC) 是一種高效生物藥物，由靶向腫瘤的抗體透過化學方式與細胞毒性效應分子連接而成。它們透過可生物分解的連接體將細胞毒性抗癌藥物與單株抗體 (mAb) 連接，從而將細胞毒性抗癌藥物遞送至受影響的細胞，並允許健康組織和患病組織之間進行靈敏的分叉。與標準化療生物活性化合物相比，ADC 有助於增強 mAb 的細胞殺傷潛力、增強藥物耐受性並降低系統性暴露。目前，它們透過靜脈注射進入血液，以避免胃酸和蛋白質水解酶分解 mAb。

抗體藥物偶聯物市場趨勢：

由於久坐不動的生活方式以及吸煙和飲酒習慣的不斷增加，全球癌症的發生率正在上升。這與對經濟高效且有效的癌症治療方案日益成長的需求相結合，是推動市場成長的關鍵因素之一。此外，現有的連接體通常會非特異性地釋放有效載荷，並導致脫靶毒性，這嚴重影響了ADC的開發。因此，領先的企業正在持續投資其研發項目，以最佳化現有的化學觸發劑，並開發新型化學觸發劑，從而產生高選擇性的連接體。他們還開發了新型的連接體-抗體連接體，以生產穩定均質的ADC，以及額外的連接體-有效載荷連接體，以擴展有效載荷。此外，他們還致力於改善藥物的吸收、分佈、代謝和排泄，這為市場前景創造了良好的前景。其他主要因素，包括顯著改善醫療保健基礎設施、提高對癌症治療方法的認知以及可裂解連接技術的引入，預計將推動市場成長。

本報告回答的關鍵問題：

全球抗體藥物偶聯物市場迄今表現如何，未來幾年將如何表現？
COVID-19 對全球抗體藥物偶聯物市場有何影響？
主要的區域市場有哪些？
根據組成部分，市場是如何分類的？
根據目標，市場區隔如何？
根據應用，市場是如何分類的？
根據最終用戶，市場是如何分類的？
該產業的價值鏈分為哪些階段？
該行業的主要促進因素和挑戰是什麼？
全球抗體藥物偶聯物市場的結構是怎麼樣的？主要參與者是誰？
產業競爭程度如何？

市場結構
關鍵參與者
關鍵參與者簡介
- ADC Therapeutics SA
- Astellas Pharma Inc.
- AstraZeneca plc
- Celldex Therapeutics Inc.
- F. Hoffmann-La Roche AG
- Gilead Sciences Inc.
- GlaxoSmithKline Plc
- ImmunoGen Inc
- Pfizer Inc.
- Sanofi SA
- Seagen Inc.
- Sorrento Therapeutics Inc.
- Takeda Pharmaceutical Company Ltd.

簡介目錄圖表

Product Code: SR112025A4604

The global antibody drug conjugates market size reached USD 9.4 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 50.2 Billion by 2033, exhibiting a growth rate (CAGR) of 19.45% during 2025-2033.

Antibody drug conjugates (ADCs) are highly potent biological drugs comprising tumor-targeting antibodies, which are chemically attached to a cytotoxic effector molecule. They deliver cytotoxic anticancer agents to affected cells by connecting them to monoclonal antibodies (mAb) through biodegradable linkers and allowing sensitive bifurcation between healthy and diseased tissues. They assist in increasing the cell-killing potential of mAb, enhancing drug tolerability, and limiting systematic exposure compared to standard chemotherapy bioactive compounds. At present, they are administered intravenously into the bloodstream to avoid gastric acid and proteolytic enzyme degradation of the mAb.

Antibody Drug Conjugates Market Trends:

Due to sedentary lifestyles and the rising number of individuals who smoke and drink regularly, there is an increase in the prevalence of cancer around the world. This, in confluence with the escalating demand for cost-effective and successful cancer treatments, represents one of the key factors bolstering the growth of the market. Apart from this, the existing linkers often release payloads nonspecifically and lead to off-target toxicity, which severely affects the development of ADCs. As a result, leading players are continuously funding their research and development (R&D) projects to optimize the existing chemical triggers and develop novel chemical triggers to generate highly selective linkers. They are also coming up with novel linker-antibody attachments to produce stable and homogenous ADCs and additional linker-payload attachments to allow the expansion of payloads. Moreover, they are focusing on improving the absorption, distribution, metabolism, and excretion, which is creating a favorable market outlook. Other major factors, including considerably improving healthcare infrastructure, increasing awareness about therapies available for cancer treatments, and the introduction of cleavable linker technology, are anticipated to propel the market growth.

Key Market Segmentation:

Breakup by Component:

Monoclonal Antibodies
Linker
Cytotoxic Agent
Others

Breakup by Target:

Antibody-Protein Toxin Conjugates
Antibody-Chelated Radionuclide Conjugates
Antibody-Small-Molecule Drug Conjugates
Antibody-Enzyme Conjugates

Breakup by Application:

Lymphoma
Ovarian Cancer
Lung Cancer
Breast Cancer
Brain Tumor
Others

Breakup by End User:

Hospitals
Specialized Cancer Centers
Academic Research Institutes
Biotechnology Companies
Others

Breakup by Region:

North America
- United States
- Canada
Asia-Pacific
- China
- Japan
- India
- South Korea
- Australia
- Indonesia
- Others
Europe
- Germany
- France
- United Kingdom
- Italy
- Spain
- Russia
- Others
Latin America
- Brazil
- Mexico
- Others
Middle East and Africa

Competitive Landscape:

The competitive landscape of the industry has also been examined along with the profiles of the key players being ADC Therapeutics SA, Astellas Pharma Inc., AstraZeneca plc, Celldex Therapeutics Inc., F. Hoffmann-La Roche AG, Gilead Sciences Inc., GlaxoSmithKline Plc, ImmunoGen Inc, Pfizer Inc., Sanofi S.A., Seagen Inc., Sorrento Therapeutics Inc. and Takeda Pharmaceutical Company Ltd.

Key Questions Answered in This Report:

How has the global antibody drug conjugates market performed so far and how will it perform in the coming years?
What has been the impact of COVID-19 on the global antibody drug conjugates market?
What are the key regional markets?
What is the breakup of the market based on the component?
What is the breakup of the market based on the target?
What is the breakup of the market based on the application?
What is the breakup of the market based on the end user?
What are the various stages in the value chain of the industry?
What are the key driving factors and challenges in the industry?
What is the structure of the global antibody drug conjugates market and who are the key players?
What is the degree of competition in the industry?

1 Preface

2 Scope and Methodology

2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
- 2.3.1 Primary Sources
- 2.3.2 Secondary Sources
2.4 Market Estimation
- 2.4.1 Bottom-Up Approach
- 2.4.2 Top-Down Approach
2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

4.1 Overview
4.2 Key Industry Trends

5 Global Antibody Drug Conjugates Market

5.1 Market Overview
5.2 Market Performance
5.3 Impact of COVID-19
5.4 Market Forecast

6 Market Breakup by Component

6.1 Monoclonal Antibodies
- 6.1.1 Market Trends
- 6.1.2 Market Forecast
6.2 Linker
- 6.2.1 Market Trends
- 6.2.2 Market Forecast
6.3 Cytotoxic Agent
- 6.3.1 Market Trends
- 6.3.2 Market Forecast
6.4 Others
- 6.4.1 Market Trends
- 6.4.2 Market Forecast

7 Market Breakup by Target

7.1 Antibody-Protein Toxin Conjugates
- 7.1.1 Market Trends
- 7.1.2 Market Forecast
7.2 Antibody-Chelated Radionuclide Conjugates
- 7.2.1 Market Trends
- 7.2.2 Market Forecast
7.3 Antibody-Small-Molecule Drug Conjugates
- 7.3.1 Market Trends
- 7.3.2 Market Forecast
7.4 Antibody-Enzyme Conjugates
- 7.4.1 Market Trends
- 7.4.2 Market Forecast

8 Market Breakup by Application

8.1 Lymphoma
- 8.1.1 Market Trends
- 8.1.2 Market Forecast
8.2 Ovarian Cancer
- 8.2.1 Market Trends
- 8.2.2 Market Forecast
8.3 Lung Cancer
- 8.3.1 Market Trends
- 8.3.2 Market Forecast
8.4 Breast Cancer
- 8.4.1 Market Trends
- 8.4.2 Market Forecast
8.5 Brain Tumor
- 8.5.1 Market Trends
- 8.5.2 Market Forecast
8.6 Others
- 8.6.1 Market Trends
- 8.6.2 Market Forecast

9 Market Breakup by End User

9.1 Hospitals
- 9.1.1 Market Trends
- 9.1.2 Market Forecast
9.2 Specialized Cancer Centers
- 9.2.1 Market Trends
- 9.2.2 Market Forecast
9.3 Academic Research Institutes
- 9.3.1 Market Trends
- 9.3.2 Market Forecast
9.4 Biotechnology Companies
- 9.4.1 Market Trends
- 9.4.2 Market Forecast
9.5 Others
- 9.5.1 Market Trends
- 9.5.2 Market Forecast

10 Market Breakup by Region

10.1 North America
- 10.1.1 United States
  - 10.1.1.1 Market Trends
  - 10.1.1.2 Market Forecast
- 10.1.2 Canada
  - 10.1.2.1 Market Trends
  - 10.1.2.2 Market Forecast
10.2 Asia-Pacific
- 10.2.1 China
  - 10.2.1.1 Market Trends
  - 10.2.1.2 Market Forecast
- 10.2.2 Japan
  - 10.2.2.1 Market Trends
  - 10.2.2.2 Market Forecast
- 10.2.3 India
  - 10.2.3.1 Market Trends
  - 10.2.3.2 Market Forecast
- 10.2.4 South Korea
  - 10.2.4.1 Market Trends
  - 10.2.4.2 Market Forecast
- 10.2.5 Australia
  - 10.2.5.1 Market Trends
  - 10.2.5.2 Market Forecast
- 10.2.6 Indonesia
  - 10.2.6.1 Market Trends
  - 10.2.6.2 Market Forecast
- 10.2.7 Others
  - 10.2.7.1 Market Trends
  - 10.2.7.2 Market Forecast
10.3 Europe
- 10.3.1 Germany
  - 10.3.1.1 Market Trends
  - 10.3.1.2 Market Forecast
- 10.3.2 France
  - 10.3.2.1 Market Trends
  - 10.3.2.2 Market Forecast
- 10.3.3 United Kingdom
  - 10.3.3.1 Market Trends
  - 10.3.3.2 Market Forecast
- 10.3.4 Italy
  - 10.3.4.1 Market Trends
  - 10.3.4.2 Market Forecast
- 10.3.5 Spain
  - 10.3.5.1 Market Trends
  - 10.3.5.2 Market Forecast
- 10.3.6 Russia
  - 10.3.6.1 Market Trends
  - 10.3.6.2 Market Forecast
- 10.3.7 Others
  - 10.3.7.1 Market Trends
  - 10.3.7.2 Market Forecast
10.4 Latin America
- 10.4.1 Brazil
  - 10.4.1.1 Market Trends
  - 10.4.1.2 Market Forecast
- 10.4.2 Mexico
  - 10.4.2.1 Market Trends
  - 10.4.2.2 Market Forecast
- 10.4.3 Others
  - 10.4.3.1 Market Trends
  - 10.4.3.2 Market Forecast
10.5 Middle East and Africa
- 10.5.1 Market Trends
- 10.5.2 Market Breakup by Country
- 10.5.3 Market Forecast

11 SWOT Analysis

11.1 Overview
11.2 Strengths
11.3 Weaknesses
11.4 Opportunities
11.5 Threats

12 Value Chain Analysis

13 Porters Five Forces Analysis

13.1 Overview
13.2 Bargaining Power of Buyers
13.3 Bargaining Power of Suppliers
13.4 Degree of Competition
13.5 Threat of New Entrants
13.6 Threat of Substitutes

14 Price Analysis

15 Competitive Landscape

15.1 Market Structure
15.2 Key Players
15.3 Profiles of Key Players
- 15.3.1 ADC Therapeutics SA
  - 15.3.1.1 Company Overview
  - 15.3.1.2 Product Portfolio
  - 15.3.1.3 Financials
- 15.3.2 Astellas Pharma Inc.
  - 15.3.2.1 Company Overview
  - 15.3.2.2 Product Portfolio
  - 15.3.2.3 Financials
  - 15.3.2.4 SWOT Analysis
- 15.3.3 AstraZeneca plc
  - 15.3.3.1 Company Overview
  - 15.3.3.2 Product Portfolio
  - 15.3.3.3 Financials
  - 15.3.3.4 SWOT Analysis
- 15.3.4 Celldex Therapeutics Inc.
  - 15.3.4.1 Company Overview
  - 15.3.4.2 Product Portfolio
  - 15.3.4.3 Financials
  - 15.3.4.4 SWOT Analysis
- 15.3.5 F. Hoffmann-La Roche AG
  - 15.3.5.1 Company Overview
  - 15.3.5.2 Product Portfolio
  - 15.3.5.3 Financials
- 15.3.6 Gilead Sciences Inc.
  - 15.3.6.1 Company Overview
  - 15.3.6.2 Product Portfolio
  - 15.3.6.3 Financials
  - 15.3.6.4 SWOT Analysis
- 15.3.7 GlaxoSmithKline Plc
  - 15.3.7.1 Company Overview
  - 15.3.7.2 Product Portfolio
  - 15.3.7.3 Financials
  - 15.3.7.4 SWOT Analysis
- 15.3.8 ImmunoGen Inc
  - 15.3.8.1 Company Overview
  - 15.3.8.2 Product Portfolio
  - 15.3.8.3 Financials
  - 15.3.8.4 SWOT Analysis
- 15.3.9 Pfizer Inc.
  - 15.3.9.1 Company Overview
  - 15.3.9.2 Product Portfolio
  - 15.3.9.3 Financials
  - 15.3.9.4 SWOT Analysis
- 15.3.10 Sanofi S.A.
  - 15.3.10.1 Company Overview
  - 15.3.10.2 Product Portfolio
  - 15.3.10.3 Financials
  - 15.3.10.4 SWOT Analysis
- 15.3.11 Seagen Inc.
  - 15.3.11.1 Company Overview
  - 15.3.11.2 Product Portfolio
  - 15.3.11.3 Financials
  - 15.3.11.4 SWOT Analysis
- 15.3.12 Sorrento Therapeutics Inc.
  - 15.3.12.1 Company Overview
  - 15.3.12.2 Product Portfolio
  - 15.3.12.3 Financials
- 15.3.13 Takeda Pharmaceutical Company Ltd.
  - 15.3.13.1 Company Overview
  - 15.3.13.2 Product Portfolio
  - 15.3.13.3 Financials
  - 15.3.13.4 SWOT Analysis

簡介目錄圖表

List of Figures

Figure 1: Global: Antibody Drug Conjugates Market: Major Drivers and Challenges
Figure 2: Global: Antibody Drug Conjugates Market: Sales Value (in Billion USD), 2019-2024
Figure 3: Global: Antibody Drug Conjugates Market Forecast: Sales Value (in Billion USD), 2025-2033
Figure 4: Global: Antibody Drug Conjugates Market: Breakup by Component (in %), 2024
Figure 5: Global: Antibody Drug Conjugates Market: Breakup by Target (in %), 2024
Figure 6: Global: Antibody Drug Conjugates Market: Breakup by Application (in %), 2024
Figure 7: Global: Antibody Drug Conjugates Market: Breakup by End User (in %), 2024
Figure 8: Global: Antibody Drug Conjugates Market: Breakup by Region (in %), 2024
Figure 9: Global: Antibody Drug Conjugates (Monoclonal Antibodies) Market: Sales Value (in Million USD), 2019 & 2024
Figure 10: Global: Antibody Drug Conjugates (Monoclonal Antibodies) Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 11: Global: Antibody Drug Conjugates (Linker) Market: Sales Value (in Million USD), 2019 & 2024
Figure 12: Global: Antibody Drug Conjugates (Linker) Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 13: Global: Antibody Drug Conjugates (Cytotoxic Agent) Market: Sales Value (in Million USD), 2019 & 2024
Figure 14: Global: Antibody Drug Conjugates (Cytotoxic Agent) Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 15: Global: Antibody Drug Conjugates (Other Components) Market: Sales Value (in Million USD), 2019 & 2024
Figure 16: Global: Antibody Drug Conjugates (Other Components) Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 17: Global: Antibody Drug Conjugates (Antibody-Protein Toxin Conjugates) Market: Sales Value (in Million USD), 2019 & 2024
Figure 18: Global: Antibody Drug Conjugates (Antibody-Protein Toxin Conjugates) Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 19: Global: Antibody Drug Conjugates (Antibody-Chelated Radionuclide Conjugates) Market: Sales Value (in Million USD), 2019 & 2024
Figure 20: Global: Antibody Drug Conjugates (Antibody-Chelated Radionuclide Conjugates) Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 21: Global: Antibody Drug Conjugates (Antibody-Small-Molecule Drug Conjugates) Market: Sales Value (in Million USD), 2019 & 2024
Figure 22: Global: Antibody Drug Conjugates (Antibody-Small-Molecule Drug Conjugates) Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 23: Global: Antibody Drug Conjugates (Antibody-Enzyme Conjugates) Market: Sales Value (in Million USD), 2019 & 2024
Figure 24: Global: Antibody Drug Conjugates (Antibody-Enzyme Conjugates) Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 25: Global: Antibody Drug Conjugates (Lymphoma) Market: Sales Value (in Million USD), 2019 & 2024
Figure 26: Global: Antibody Drug Conjugates (Lymphoma) Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 27: Global: Antibody Drug Conjugates (Ovarian Cancer) Market: Sales Value (in Million USD), 2019 & 2024
Figure 28: Global: Antibody Drug Conjugates (Ovarian Cancer) Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 29: Global: Antibody Drug Conjugates (Lung Cancer) Market: Sales Value (in Million USD), 2019 & 2024
Figure 30: Global: Antibody Drug Conjugates (Lung Cancer) Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 31: Global: Antibody Drug Conjugates (Breast Cancer) Market: Sales Value (in Million USD), 2019 & 2024
Figure 32: Global: Antibody Drug Conjugates (Breast Cancer) Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 33: Global: Antibody Drug Conjugates (Brain Tumor) Market: Sales Value (in Million USD), 2019 & 2024
Figure 34: Global: Antibody Drug Conjugates (Brain Tumor) Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 35: Global: Antibody Drug Conjugates (Other Applications) Market: Sales Value (in Million USD), 2019 & 2024
Figure 36: Global: Antibody Drug Conjugates (Other Applications) Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 37: Global: Antibody Drug Conjugates (Hospitals) Market: Sales Value (in Million USD), 2019 & 2024
Figure 38: Global: Antibody Drug Conjugates (Hospitals) Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 39: Global: Antibody Drug Conjugates (Specialized Cancer Centers) Market: Sales Value (in Million USD), 2019 & 2024
Figure 40: Global: Antibody Drug Conjugates (Specialized Cancer Centers) Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 41: Global: Antibody Drug Conjugates (Academic Research Institutes) Market: Sales Value (in Million USD), 2019 & 2024
Figure 42: Global: Antibody Drug Conjugates (Academic Research Institutes) Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 43: Global: Antibody Drug Conjugates (Biotechnology Companies) Market: Sales Value (in Million USD), 2019 & 2024
Figure 44: Global: Antibody Drug Conjugates (Biotechnology Companies) Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 45: Global: Antibody Drug Conjugates (Other End Users) Market: Sales Value (in Million USD), 2019 & 2024
Figure 46: Global: Antibody Drug Conjugates (Other End Users) Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 47: North America: Antibody Drug Conjugates Market: Sales Value (in Million USD), 2019 & 2024
Figure 48: North America: Antibody Drug Conjugates Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 49: United States: Antibody Drug Conjugates Market: Sales Value (in Million USD), 2019 & 2024
Figure 50: United States: Antibody Drug Conjugates Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 51: Canada: Antibody Drug Conjugates Market: Sales Value (in Million USD), 2019 & 2024
Figure 52: Canada: Antibody Drug Conjugates Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 53: Asia-Pacific: Antibody Drug Conjugates Market: Sales Value (in Million USD), 2019 & 2024
Figure 54: Asia-Pacific: Antibody Drug Conjugates Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 55: China: Antibody Drug Conjugates Market: Sales Value (in Million USD), 2019 & 2024
Figure 56: China: Antibody Drug Conjugates Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 57: Japan: Antibody Drug Conjugates Market: Sales Value (in Million USD), 2019 & 2024
Figure 58: Japan: Antibody Drug Conjugates Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 59: India: Antibody Drug Conjugates Market: Sales Value (in Million USD), 2019 & 2024
Figure 60: India: Antibody Drug Conjugates Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 61: South Korea: Antibody Drug Conjugates Market: Sales Value (in Million USD), 2019 & 2024
Figure 62: South Korea: Antibody Drug Conjugates Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 63: Australia: Antibody Drug Conjugates Market: Sales Value (in Million USD), 2019 & 2024
Figure 64: Australia: Antibody Drug Conjugates Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 65: Indonesia: Antibody Drug Conjugates Market: Sales Value (in Million USD), 2019 & 2024
Figure 66: Indonesia: Antibody Drug Conjugates Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 67: Others: Antibody Drug Conjugates Market: Sales Value (in Million USD), 2019 & 2024
Figure 68: Others: Antibody Drug Conjugates Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 69: Europe: Antibody Drug Conjugates Market: Sales Value (in Million USD), 2019 & 2024
Figure 70: Europe: Antibody Drug Conjugates Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 71: Germany: Antibody Drug Conjugates Market: Sales Value (in Million USD), 2019 & 2024
Figure 72: Germany: Antibody Drug Conjugates Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 73: France: Antibody Drug Conjugates Market: Sales Value (in Million USD), 2019 & 2024
Figure 74: France: Antibody Drug Conjugates Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 75: United Kingdom: Antibody Drug Conjugates Market: Sales Value (in Million USD), 2019 & 2024
Figure 76: United Kingdom: Antibody Drug Conjugates Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 77: Italy: Antibody Drug Conjugates Market: Sales Value (in Million USD), 2019 & 2024
Figure 78: Italy: Antibody Drug Conjugates Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 79: Spain: Antibody Drug Conjugates Market: Sales Value (in Million USD), 2019 & 2024
Figure 80: Spain: Antibody Drug Conjugates Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 81: Russia: Antibody Drug Conjugates Market: Sales Value (in Million USD), 2019 & 2024
Figure 82: Russia: Antibody Drug Conjugates Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 83: Others: Antibody Drug Conjugates Market: Sales Value (in Million USD), 2019 & 2024
Figure 84: Others: Antibody Drug Conjugates Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 85: Latin America: Antibody Drug Conjugates Market: Sales Value (in Million USD), 2019 & 2024
Figure 86: Latin America: Antibody Drug Conjugates Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 87: Brazil: Antibody Drug Conjugates Market: Sales Value (in Million USD), 2019 & 2024
Figure 88: Brazil: Antibody Drug Conjugates Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 89: Mexico: Antibody Drug Conjugates Market: Sales Value (in Million USD), 2019 & 2024
Figure 90: Mexico: Antibody Drug Conjugates Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 91: Others: Antibody Drug Conjugates Market: Sales Value (in Million USD), 2019 & 2024
Figure 92: Others: Antibody Drug Conjugates Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 93: Middle East and Africa: Antibody Drug Conjugates Market: Sales Value (in Million USD), 2019 & 2024
Figure 94: Middle East and Africa: Antibody Drug Conjugates Market: Breakup by Country (in %), 2024
Figure 95: Middle East and Africa: Antibody Drug Conjugates Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 96: Global: Antibody Drug Conjugates Industry: SWOT Analysis
Figure 97: Global: Antibody Drug Conjugates Industry: Value Chain Analysis
Figure 98: Global: Antibody Drug Conjugates Industry: Porter's Five Forces Analysis

List of Tables

Table 1: Global: Antibody Drug Conjugates Market: Key Industry Highlights, 2024 and 2033
Table 2: Global: Antibody Drug Conjugates Market Forecast: Breakup by Component (in Million USD), 2025-2033
Table 3: Global: Antibody Drug Conjugates Market Forecast: Breakup by Target (in Million USD), 2025-2033
Table 4: Global: Antibody Drug Conjugates Market Forecast: Breakup by Application (in Million USD), 2025-2033
Table 5: Global: Antibody Drug Conjugates Market Forecast: Breakup by End User (in Million USD), 2025-2033
Table 6: Global: Antibody Drug Conjugates Market Forecast: Breakup by Region (in Million USD), 2025-2033
Table 7: Global: Antibody Drug Conjugates Market: Competitive Structure
Table 8: Global: Antibody Drug Conjugates Market: Key Players

02-2729-4219

+886-2-2729-4219